JAKARTA. PT Kalbe Farma Tbk (KLBF) has obtained approval from the National Agency of Drug and Food Control (BPOM) for its clinical testing of 2b/3 stage of the GX-19N COVID-19 vaccine in Indonesia. It is targeted to be completed by the end of 2021.
Irawati Setiady, President Commissary of Kalbe Farma, states that the GX-19N development would be continued considering the COVID-19 vaccine supply in Indonesia has not yet met the public’s demand. “Should the 2b/3 stage testing be deemed successful and gain an emergency use authorisation from BPOM, the GX-19N would add to the existing vaccine supply,” he confirms in the press conference received by idnfinancials.com.
Once the clinical testing of GX-19N generated adequate results and obtained the emergency use authorisation, the new vaccine would become an alternative to other existing COVID-19 vaccines in Indonesia. KLBF has promised to provide 10 million doses of the GX-19N vaccine.
GX-19N is a vaccine developed by Kalbe Farma and Genexine, a pharmaceutical company based in South Korea. Other pharmaceutical companies also participate in this vaccine development consortium. The previous stages of testing, 1 and 2a, had been performed in South Korea.
For this current 2b/3 phase, the clinical testing would also be conducted in several countries, such as Turkey, India, UAE, Mexico, etc. The total volunteers participating in this stage reach over 30 thousand people. (KR/ZH)